By Mill Chart
Last update: Jan 2, 2024
DEXCOM INC (NASDAQ:DXCM) has caught the eye of our stock screener as an affordable growth stock. NASDAQ:DXCM is displaying robust growth metrics and also excels in terms of profitability, solvency, and liquidity. Additionally, it appears to be reasonably priced. Let's delve into the details.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:DXCM was assigned a score of 9 for growth:
ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:DXCM boasts a 5 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:DXCM has earned a 6 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:DXCM scores a 8 out of 10:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
Check the latest full fundamental report of DXCM for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
DEXCOM INC
NASDAQ:DXCM (4/19/2024, 7:00:00 PM)
After market: 129.32 -1.39 (-1.06%)130.71
-3.59 (-2.67%)
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
This April, discover three game-changing tech stocks with disruptive technologies poised to future-proof your portfolio in 2024.
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout.
DoorDash, DexCom, and Advanced Micro Devices are three Nasdaq stocks to sell before reality sets in as exuberance may be fading.
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments
The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83.
These healthcare companies' target markets substantially overlap.